Literature DB >> 22076433

Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model.

Noriyuki Sugiyama1, Michiaki Kohno, Takahiko Yokoyama.   

Abstract

BACKGROUND: Nephronophthisis (NPHP), the most frequent genetic cause of end-stage kidney disease in children and young adults, is characterized by a variable number of renal cysts associated with cortical tubular atrophy and interstitial fibrosis. The p38 mitogen-activated protein kinase (MAPK) pathway is an important intracellular signaling pathway involved in the production of profibrotic mediators. The relationship between p38 MAPK and renal fibrosis in NPHP2 is unknown.
METHODS: We administered a selective p38 MAPK inhibitor, FR167653, in a NPHP2 mouse model (inv/inv, invΔC mice) from 3 to 6 weeks old, and the kidneys were examined at 6 weeks of age. Phosphorylation of p38 MAPK (p-p38 MAPK) protein levels, the degree of renal fibrosis, messenger RNA (mRNA) levels for extracellular matrix genes and mRNA levels for transforming growth factor in the kidneys were studied. Effect of an extracellular signal-regulated protein kinase (ERK) kinase (MEK) inhibitor on renal fibrosis was also evaluated.
RESULTS: Expression of extracellular matrix genes and p-p38 MAPK were increased in the NPHP2 mouse model kidney. FR167653 successfully decreased p-p38 MAPK levels, the degree of fibrosis and extracellular matrix gene expressions. However, the FR167653 did not prevent cyst expansion, abnormal cell proliferation and acceleration of apoptosis and did not influence ERK activation. In contrast, MEK inhibition reduced both cyst expansion and fibrosis without affecting p38 MAPK activation.
CONCLUSIONS: These results suggest that inhibition of p38 MAPK reduced renal fibrosis but not cyst expansion, cell proliferation and apoptosis in NPHP2 model mice. Our results suggest that p38 MAPK and ERK signaling pathways independently affect renal fibrosis in inv mutant mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076433     DOI: 10.1093/ndt/gfr550

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  25 in total

Review 1.  Ciliopathies: the trafficking connection.

Authors:  Kayalvizhi Madhivanan; Ruben Claudio Aguilar
Journal:  Traffic       Date:  2014-08-11       Impact factor: 6.215

Review 2.  Tryptophan metabolites kynurenine and serotonin regulate fibroblast activation and fibrosis.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

Review 3.  Nephronophthisis: should we target cysts or fibrosis?

Authors:  Gisela G Slaats; Marc R Lilien; Rachel H Giles
Journal:  Pediatr Nephrol       Date:  2015-07-29       Impact factor: 3.714

4.  FGF2-mediated attenuation of myofibroblast activation is modulated by distinct MAPK signaling pathways in human dermal fibroblasts.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  J Dermatol Sci       Date:  2017-09-01       Impact factor: 4.563

5.  Clinical and genetic characteristics of Japanese nephronophthisis patients.

Authors:  Keisuke Sugimoto; Tomoki Miyazawa; Takuji Enya; Hitomi Nishi; Kohei Miyazaki; Mitsuru Okada; Tsukasa Takemura
Journal:  Clin Exp Nephrol       Date:  2015-10-23       Impact factor: 2.801

Review 6.  Renal Ciliopathies: Sorting Out Therapeutic Approaches for Nephronophthisis.

Authors:  Marijn F Stokman; Sophie Saunier; Alexandre Benmerah
Journal:  Front Cell Dev Biol       Date:  2021-05-13

Review 7.  Present and future in the treatment of diabetic kidney disease.

Authors:  Borja Quiroga; David Arroyo; Gabriel de Arriba
Journal:  J Diabetes Res       Date:  2015-04-07       Impact factor: 4.011

8.  Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury.

Authors:  Takaomi Adachi; Noriyuki Sugiyama; Tatsuro Gondai; Hideo Yagita; Takahiko Yokoyama
Journal:  Acta Histochem Cytochem       Date:  2013-11-22       Impact factor: 1.938

Review 9.  Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.

Authors:  Alexandros Marios Sofias; Federica De Lorenzi; Quim Peña; Armin Azadkhah Shalmani; Mihael Vucur; Jiong-Wei Wang; Fabian Kiessling; Yang Shi; Lorena Consolino; Gert Storm; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2021-06-15       Impact factor: 15.470

Review 10.  Dissecting the Involvement of Ras GTPases in Kidney Fibrosis.

Authors:  José M Muñoz-Félix; Carlos Martínez-Salgado
Journal:  Genes (Basel)       Date:  2021-05-24       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.